Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olav Dalgard

Showing results (41-50 of 107) with videos related to

Pageof 11
Sort By:
Plos One|June 24, 2021
Mortality among amphetamine users with hepatitis C virus infection: A nationwide studyCaroline Gahrton, Anders Håkansson, Martin Kåberg, et al.
Hepatology (Baltimore, Md.)|November 24, 2004
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot studyOlav Dalgard, Kristian Bjøro, Kjell Block Hellum, et al.
Scandinavian Journal of Gastroenterology|September 4, 2019
The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patientsRachna Shridhar Gulati, Thakshani Wimalanathan, Solveig Norheim Andersen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 1, 2022
Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugsHåvard Midgard, Ronny Bjørnestad, Maren Egeland, et al.
The International Journal on Drug Policy|December 7, 2023
Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugsEirik Opheim, Olav Dalgard, Kjersti Ulstein, et al.
Journal of Hepatology|February 8, 2017
Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis CJason Grebely, Tracy Swan, Matthew Hickman, et al.
Substance Abuse Treatment, Prevention, and Policy|March 27, 2024
Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort studyKarl Trygve Druckrey-Fiskaaen, Jørn Henrik Vold, Tesfaye Madebo, et al.
Scientific Reports|December 19, 2023
Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokinesMarte Holmberg, Hans Christian D Aass, Olav Dalgard, et al.
BMC Infectious Diseases|August 5, 2017
Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030Hinta Meijerink, Richard A White, Astrid Løvlie, et al.
The International Journal on Drug Policy|May 7, 2023
Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based studyKristian Braathen Malme, Kjersti Ulstein, Ane-Kristine Finbråten, et al.
Pageof 11

Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Plos One|June 24, 2021
Mortality among amphetamine users with hepatitis C virus infection: A nationwide studyCaroline Gahrton, Anders Håkansson, Martin Kåberg, et al.
Hepatology (Baltimore, Md.)|November 24, 2004
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot studyOlav Dalgard, Kristian Bjøro, Kjell Block Hellum, et al.
Scandinavian Journal of Gastroenterology|September 4, 2019
The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patientsRachna Shridhar Gulati, Thakshani Wimalanathan, Solveig Norheim Andersen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 1, 2022
Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugsHåvard Midgard, Ronny Bjørnestad, Maren Egeland, et al.
The International Journal on Drug Policy|December 7, 2023
Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugsEirik Opheim, Olav Dalgard, Kjersti Ulstein, et al.
Journal of Hepatology|February 8, 2017
Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis CJason Grebely, Tracy Swan, Matthew Hickman, et al.
Substance Abuse Treatment, Prevention, and Policy|March 27, 2024
Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort studyKarl Trygve Druckrey-Fiskaaen, Jørn Henrik Vold, Tesfaye Madebo, et al.
Scientific Reports|December 19, 2023
Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokinesMarte Holmberg, Hans Christian D Aass, Olav Dalgard, et al.
BMC Infectious Diseases|August 5, 2017
Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030Hinta Meijerink, Richard A White, Astrid Løvlie, et al.
The International Journal on Drug Policy|May 7, 2023
Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based studyKristian Braathen Malme, Kjersti Ulstein, Ane-Kristine Finbråten, et al.
Pageof 11